The Praxeon team combines our deep expertise in
  • Semantic Fingerprinting™ and related Health 2.0 technologies
  • Clinical medicine
  • Discovery informatics
  • Computational chemistry
  • Medicinal chemistry
to deliver innovative solutions to challenging problems facing health care consumers, health care providers, pharmaceutical R&D and healthcare IT.

Learn More

Health Care Solutions

Praxeon has been a pioneer in the Health 2.0 movement since its inception. Our innovative and award-winning approaches to health care are showcased in our consumer health site MyDailyApple and our professional site Curbside.MD.

Praxeon health care solutions are built on the Praxeon API, a cloud-based web service which provides features such as:

  • Intelligent search
  • Content organization
  • Content navigation
  • Active news and alerts

Our Health Care projects typically commence with a pilot or proof of concept, in which we orient a new customer to the Praxeon API and customize MyDailyApple or Curbside.MD to demonstrate:

  • Targeted content
  • Contextualized organization
  • Health profile integration
  • Other custom features
Contact us today for more details.

R&D Solutions

The Praxeon team has been designing and delivering cutting-edge solutions for R&D for over 20 years.

Data Infrastructure

Learn more in our Data Platform Services solution overview (PDF format).

Computational Sciences

  • Targeted discovery of lead compounds for all biological targets.
  • Enhancing the quality of compound selection by sophisticated med-chem and ADMET liability filtering.
  • SAR analysis and progressing hit compounds into lead optimization.
  • Use of structural information to guide optimization and selectivity.
  • Development of pharmacophoric models to guide lead optimization and selectivity and to improve the off target toxicity risk profile.
  • Calculation of ADMET properties and guidance to reduce liabilities.
  • Analysis of complex multifaceted chemical, biological and genomic data.
  • Development of novel targets for therapeutic intervention using proprietary software.
  • Fluent in GPCRs, kinases, proteases, viral reverse transcriptases, ion channels, nuclear hormone receptors, RNA, CNS, etc. as drug targets.
  • Management of CROs driving return on investment.
  • Development of R&D strategic plans and tactical implementation plans.
  • Risk analysis of new targets, evaluation of IP and competitive analysis of assets.
  • Strengthening IP portfolios through directed exploration of very large libraries of compounds.